AstraZeneca to pay $520 million in US Seroquel off-label probe
This article was originally published in Scrip
Executive Summary
AstraZeneca has reached a $520 million agreement in principle to resolve an investigation by the Philadelphia office of the US Department of Justice into the company's sales and marketing practices for its antipsychotic Seroquel (quetiapine fumarate), including allegations that the company promoted the product for off-label uses.